April 3, 2014, Seattle WA,,TapImmune Inc. (OTCQB: TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on the most recent corporate events and milestones for the year ahead. Glynn Wilson TapImmunes’ CEO provided insights in an interview on the floor of the NASDAQ recently which can be seen by navigating to the following link: <Click here to View CEO Interview>
Management believes that the TapImmune platform technologies combine to make the most comprehensive vaccines in development today. The comprehensive approach of stimulating both the helper and killer T cell response to cancer antigens is essential in having an effective and long lasting killing effect on tumor and infected cells.
On March 3rd the company announced positive interim data on the Phase l clinical trial in Her2/neu positive breast cancer. The TPIV vaccines address a significant unmet market need. They are applicable to a much larger and broader patient population than current ‘standard of care’ therapies like Herceptin by Roche which is useful for only 15-20% of the Her2neu Breast Cancer patient population. Herceptin is not designed to kill tumor cells (it slows tumor growth). 2013 Herceptin sales exceeded $6B. TPIV vaccine is applicable to over 50% of the Her2neu patient population AND is also not limited to breast cancer indications. Her2neu is a target for TPIV in both Colorectal and Ovarian cancer where there are very few therapeutic options.
The TPIV Her2neu vaccine combination is unique in that it is designed to stimulate KILLER T Cells and the HELPER T Cells that are needed to SUSTAIN the KILLER cells for a LONG LASTING vaccine that kills tumor cells. In regard to our killer T-cell antigen, Ppublished data also supports a 5 fold increase in killing efficacy compared to the development vaccine Neuvax by Galena. TPIV100 is completing Phase 1 with Phase lb/ll scheduled to start in Q4 2014.